Milestones MIT Professor Leonard Guarente (Lenny), Novartis Professor of Ageing, has joined Sibelius Advisory board.7th June 2016 Dr. Sasha Akoulitchev to present at SupplySide West Vendor Briefings on Wednesday 7th October, 4.30pm, booth 400.15th September 2015 Sibelius is expanding and relocating to new laboratory space at Beaumont Street Oxford6th August 2015 Antoine Verslype appointed Laboratory Manager10th April 2015 Dr Pete Appleford appointed Research Fellow18th November 2014 Scale-up Doubles Screening Capacity17th June 2014 Sibelius Signs Partnership Agreement with Biox Singapore17th May 2014 Sibelius Signs Screening Contract with Cape Kingdom17th April 2014 9 Sibelius Proprietary Products Developed6th October 2013 Sibelius Signs Contract with Creeyan1st August 2013 Type II Diabetes Mellitus Screening30th July 2013 Development of Third Proprietary Product18th February 2013 High Through-Put Mechanism of Action Screening14th January 2013 Novel Proprietary Anti-Ageing Compound Discovered10th October 2012 Development of Second Proprietary Product17th September 2012 Successful Synergistic Combinations Identified10th September 2012 Development of Proprietary Product17th August 2012 Novel Proprietary High Throughput Screening Developed13th August 2012 Second Research Testing Agreement Signed with World Leading Cosmeceutical Company13th June 2012 Review Validates Sibelius’ Therapeutic Approach11th February 2012 Research and Testing Agreement Signed with World Leading Cosmeceutical Company1st November 2011 Eu Yang San Testing & Development Agreement28th October 2011 Development of Sibelius Proprietary Formulation6th October 2011 Health and Wellness Innovations signs Licence Agreement with Sibelius20th September 2011 Sibelius Validates Synergistic Extension of Chronological Life Span17th July 2011 Successful Proof Principal Mouse Trial with Chronoscreen™ Validated Compound15th June 2011 Eu Yan Sang Signs Development Contract with Sibelius28th May 2011 CellResearch Corp signs development contract with Sibelius21st May 2011 RDC5 Reduces the Levels of Toxic Protein Aggregates9th December 2010 Completion of the 30,000 compound analysis in Chronoscreen™ Initiated in February 20101st October 2010
